Drug · CHEMBL140
CURCUMIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CURCUMIN. Drugs and targets, record CHEMBL140. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL140
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
C.i. 75300, C.i. natural yellow 3, Ci 75300, Ci-75300, Curcumin e100, Diferuloylmethane, E 100, E-100, E100, Haldar, INS NO. 100(I), INS-100(I), Jianghuangsu, Kacha haldi, Kurkum, Lipocurc, Merita earth, NSC-32982, NSC-687842, Nanocurc, Turmeric yellow
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases82
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 82Source Open Targets
See all 82 diseasesTrials165
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 18 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01246973 | Oral Curcumin for Radiation Dermatitis | Phase 2/3 | 686 | 2016-03-07 | curcumin | Its name | ClinicalTrials.gov |
| NCT04846231 | Supplements, Placebo, or Rosuvastatin Study | Phase 2 | 203 | 2023-05-25 | turmeric | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT02556632 | Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer | Phase 2 | 191 | 2017-11-06 | curcumin | Its name | ClinicalTrials.gov |
| NCT03223883 | Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease | Phase 2 | 94 | 2024-10-08 | curcumin | Its name | ClinicalTrials.gov |
| NCT01514370 | Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a | Phase 2 | 80 | 2019-01-22 | curcumin | Its name | ClinicalTrials.gov |
| NCT02494141 | Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD | Phase 4 | 68 | 2022-03-03 | curcumin | Its name | ClinicalTrials.gov |
| NCT04205929 | Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users | Phase 4 | 58 | 2024-07-03 | curcumin | Its name | ClinicalTrials.gov |
| NCT00094445 | Trial of Curcumin in Advanced Pancreatic Cancer | Phase 2 | 50 | 2020-08-28 | curcumin | Its name | ClinicalTrials.gov |
| NCT02782949 | Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia | Phase 2 | 50 | 2024-03-05 | curcumin | Its name | ClinicalTrials.gov |
| NCT03584724 | Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis | Early phase 1 | 49 | 2022-03-28 | curcumin-phosphatidylcholine complex | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
1 to 10 of 165
See all 165 trialsComparisons in its trials34
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Curcumin vs Placebo: serious adverse events | 0 of 344 | 0 of 342 | 686 | NCT01246973 | Trial comparisons |
| Curcumin vs Placebo: deaths from any cause | 1 of 45 | 0 of 43 | 88 | NCT03223883 | Trial comparisons |
| Curcumin vs Placebo: serious adverse events | 0 of 45 | 0 of 43 | 88 | NCT03223883 | Trial comparisons |
| IFN Beta 1a 44 mcg TIW + Curcumin (BCM95) vs IFN Beta 1a 44 mcg TIW + Placebo: Number of Subjects With Active (New or Enlarging) T2 Lesions Assessed by Magnetic Resonance Imaging (MRI) at Month 12 | 4 of 40 | 7 of 40 | 80 | NCT01514370 | Trial comparisons |
| IFN Beta 1a 44 mcg TIW + Curcumin (BCM95) vs IFN Beta 1a 44 mcg TIW + Placebo: serious adverse events | 1 of 38 | 0 of 40 | 78 | NCT01514370 | Trial comparisons |
| Curcumin vs Placebo: deaths from any cause | 0 of 34 | 0 of 34 | 68 | NCT02494141 | Trial comparisons |
| Curcumin vs Placebo: serious adverse events | 0 of 34 | 0 of 34 | 68 | NCT02494141 | Trial comparisons |
| Curcumin Group vs Placebo Group: deaths from any cause | 0 of 29 | 0 of 29 | 58 | NCT04205929 | Trial comparisons |
| Curcumin Group vs Placebo Group: serious adverse events | 0 of 29 | 0 of 29 | 58 | NCT04205929 | Trial comparisons |
| Curcumin Group vs Placebo Group: Proportion of Participants Who Intend to Continue Use of Implant | 16 of 26 | 23 of 28 | 54 | NCT04205929 | Trial comparisons |
1 to 10 of 34
See all 34 comparisons in its trialsPapers from its trials131
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Selective Reminding Task | 1 | 1 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL140
GET https://conductscience.org/api/drugs/v1/CHEMBL140/diseases?page=2